Elutia (ELUT) Q2 2024 earnings summary

Executive summary

• EluPro, the first drug-eluting biologic envelope for cardiac and neurostimulation devices, received FDA clearance in June 2024, with manufacturing initiated and a soft launch planned for H2 2024 and full launch in January 2025.

• EluPro targets a $600M pacemaker protection market and an $8B neurostimulation device market, with expanded FDA indications and significant market white space.

• Strong physician and industry interest, with 88% of surveyed TYRX users indicating intent to switch to EluPro.

• Commercial team expanded to 26 reps, with ongoing growth and business development efforts to support EluPro and SimpliDerm launches.

• SimpliDerm and CanGaroo product lines showed year-over-year growth, despite distributor disruption.

Financial highlights

• Q2 2024 net sales were $6.3M, nearly flat year-over-year.

• CanGaroo and SimpliDerm net sales each rose 19% and 7% to $2.6M; Cardiovascular sales fell 38% to $1.1M.

• GAAP gross margin improved to 45% from 43%; adjusted gross margin rose to 58% from 56% year-over-year.

• Net loss widened to $28.2M from $10.6M, mainly due to an $18.3M non-cash warrant revaluation charge.

• Adjusted EBITDA loss improved to $2.9M from $3.4M year-over-year.

• Cash balance at June 30, 2024, was $18.2M, with an additional $13.8M from post-quarter warrant exercises.

Outlook and guidance

• EluPro soft launch is set for H2 2024, with a full commercial launch in January 2025, targeting full demand in launch hospitals.

• Continued expansion of sales force and marketing spend, scaling with revenue growth into 2025.

• Ongoing business development and R&D efforts to expand EluPro into adjacent markets and develop new products.

• Management expects continued operating losses and negative cash flows for the foreseeable future, with substantial doubt about going concern status.